Dec 3rd 2020

POPular TAVI Trial: Aspirin with or without Clopidogrel after transcatheter aortic-valve implantation

Published in the New England Journal of Medicine in October, the POPular TAVI trial randomized 665 patients under-going transcatheter aortic valve replacement to receive either aspirin alone or aspirin plus clopidogrel post-procedure.  Bleeding occurred in 15.1% of the aspirin only group and 26.6% of the dual-antiplatelet group.  There was no statistically significant difference in death from any cause, stroke, or myocardial infarction between groups.  The authors concluded that aspirin alone and not dual-antiplatelet therapy was appropriate for patients without an indication for anticoagulation under-going trans-catheter aortic valve replacement.  These findings are consistent with the ARTE trial published in 2017 in the context of balloon-expandable valves.